International Journal of Science, Strategic Management and Technology
Volume **02** Issue **05** May-**2026** | ISSN: **3108-1762 (Online)** | Impact Factor: 3.8
An International, Peer-Reviewed, Open Access Scholarly Journal Indexed in recognized academic databases

Clinical Trial Regulation in India: Challenges and Future Prospects

Author:- **Megha** *

Coauthor:- **Anisha Arya**

Email:- meghapundir.79@gmail.com

Guru Nanak College of Pharmaceutical Sciences, Dehradun

https://doi.org/10.55041/ijsmt.v2i6.114

Cite this Article: Megha, & Arya, A. (2026). Clinical Trial Regulation in India: Challenges and Future Prospects. International Journal of Science, Strategic Management and Technology, *02*(6). https://doi.org/10.55041/ijsmt.v2i6.114

Abstract

Clinical trials are fundamental to the development of safe, effective, and high-quality pharmaceutical products, vaccines, medical devices, and therapeutic interventions. India has emerged as a significant destination for clinical research due to its large patient population, diverse disease burden, skilled healthcare professionals, and cost-effective research infrastructure. However, concerns regarding ethical conduct, participant safety, informed consent, and regulatory oversight have historically challenged the growth of clinical research in the country. Over the past two decades, India has undertaken substantial regulatory reforms aimed at strengthening participant protection, improving transparency, enhancing data quality, and aligning national regulations with international standards.

This review critically examines the evolution of clinical trial regulation in India, with particular emphasis on the New Drugs and Clinical Trials Rules (NDCTR), 2019 and subsequent reforms implemented between 2020 and 2026. The paper discusses the regulatory framework governing clinical trials, the role of Ethics Committees, participant protection mechanisms, clinical trial approval and registration systems, and recent regulatory advancements. Furthermore, major challenges affecting the Indian clinical research ecosystem, including regulatory complexity, infrastructure limitations, workforce shortages, participant recruitment difficulties, and public trust concerns, are analyzed.

The review also explores future prospects and emerging trends such as artificial intelligence, decentralized clinical trials, real-world evidence generation, precision medicine, digital health technologies, and global regulatory harmonization. These innovations have the potential to transform clinical research and strengthen India's position as a global hub for biomedical innovation. Strategic recommendations are proposed to support sustainable growth, regulatory excellence, and ethical conduct in clinical research. The findings suggest that continued regulatory modernization, capacity building, technological innovation, and stakeholder engagement will be essential for ensuring the future success of India's clinical trial ecosystem.

Keywords: Clinical trials, India, NDCTR 2019, CDSCO, Ethics Committee, Clinical Trial Registry-India, Regulatory reforms, Participant protection, Artificial intelligence, Decentralized clinical trials.

Graphical Abstract



1. Introduction and Evolution of Clinical Trial Regulation in India

1.1 Introduction

Clinical trials represent a critical component of modern healthcare innovation and evidence-based medicine. They provide the scientific foundation for evaluating the safety, efficacy, quality, and performance of new drugs, vaccines, medical devices, biologics, and therapeutic interventions before their introduction into clinical practice. The integrity of clinical trials directly influences public health outcomes, regulatory decisions, and patient confidence in healthcare systems.

Globally, the pharmaceutical industry invests billions of dollars annually in clinical research to support the development of innovative therapies. Regulatory oversight plays a crucial role in ensuring that clinical trials are conducted ethically, scientifically, and transparently while protecting the rights, safety, and well-being of participants. Regulatory frameworks establish requirements for study design, informed consent, safety monitoring, data integrity, and ethical review, thereby ensuring that clinical evidence generated through research is reliable and acceptable for regulatory decision-making.

India has emerged as an increasingly important participant in global clinical research due to several unique advantages. The country possesses a large and genetically diverse population, a significant burden of communicable and non-communicable diseases, highly qualified medical professionals, and comparatively lower research costs than many developed nations. These factors have contributed to growing interest among multinational pharmaceutical companies and contract research organizations in conducting clinical trials within India (Mahajan, 2020; Bhatt, 2021).

Despite these advantages, India's clinical research environment has faced numerous challenges over the past two decades. Concerns regarding informed consent practices, participant exploitation, inadequate ethical oversight, delayed compensation for trial-related injuries, and inconsistent regulatory enforcement have periodically affected public trust and international confidence in the country's clinical research ecosystem. Consequently, India has undertaken significant regulatory reforms aimed at strengthening participant protection, enhancing transparency, and aligning domestic regulations with international standards (Nundy & Gulhati, 2020; Ghooi, 2021).

1.2 Early Development of Clinical Trial Regulation in India

The origins of clinical trial regulation in India can be traced to the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. These legal frameworks primarily focused on ensuring the quality, safety, and manufacturing standards of pharmaceutical products rather than regulating clinical research activities. During the early decades following independence, clinical research activity in India remained relatively limited, and comprehensive regulations governing human subject research were largely absent.

The expansion of the global pharmaceutical industry during the 1980s and 1990s significantly increased interest in conducting multinational clinical trials in developing countries, including India. This trend highlighted the need for stronger regulatory mechanisms capable of addressing ethical and scientific challenges associated with human subject research.

International ethical guidelines, including the Declaration of Helsinki, Good Clinical Practice (GCP) guidelines, and Council for International Organizations of Medical Sciences (CIOMS) recommendations, increasingly influenced the development of national regulatory frameworks. India began adopting international standards to facilitate participation in global clinical development programs while ensuring participant protection and scientific quality.

1.3 Schedule Y and the Modernization of Clinical Research

A major milestone in the evolution of clinical trial regulation in India occurred with the revision of Schedule Y of the Drugs and Cosmetics Rules in 2005. These amendments introduced comprehensive requirements governing clinical trial conduct and represented the country's first major attempt to align regulatory expectations with internationally accepted Good Clinical Practice principles.

The revised Schedule Y established requirements related to:

- Clinical trial approval procedures
- Responsibilities of sponsors and investigators
- Ethics Committee review
- Informed consent

- Adverse event reporting
- Good Clinical Practice compliance
- Data management and documentation

The implementation of Schedule Y significantly increased international confidence in India's clinical research capabilities and facilitated the growth of multinational clinical trial activity. During the subsequent decade, India became one of the fastest-growing destinations for outsourced clinical research due to its large patient population and cost advantages (Mahajan, 2020).

However, rapid growth also exposed weaknesses within the regulatory system. Reports of unethical practices, inadequate informed consent procedures, and concerns regarding participant safety attracted public scrutiny and judicial attention. Media coverage of alleged trial-related injuries and deaths further intensified concerns regarding regulatory oversight and accountability (Nundy & Gulhati, 2020).

1.4 Ethical Concerns and Judicial Intervention

Between 2010 and 2013, India experienced significant controversy regarding the conduct of clinical trials. Public interest litigations filed before the Supreme Court of India highlighted concerns regarding participant protection, informed consent, compensation mechanisms, and regulatory enforcement.

The Supreme Court emphasized the need for stronger safeguards to protect research participants and directed regulatory authorities to implement more rigorous oversight measures. These developments marked a turning point in Indian clinical trial governance and prompted extensive regulatory reforms.

Several important measures were introduced during this period, including:

- Mandatory registration of Ethics Committees
- Strengthened compensation mechanisms
- Audio-visual recording of informed consent
- Increased regulatory inspections
- Enhanced reporting requirements for serious adverse events

Although these reforms temporarily reduced clinical trial activity due to increased compliance requirements, they ultimately contributed to improved participant protection and greater regulatory accountability (Bhatt, 2021).

1.5 Establishment of Clinical Trial Registry–India (CTRI)

Transparency has become a central principle of modern clinical research governance. To promote accountability and public access to research information, India established the Clinical Trial Registry–India (CTRI) in 2007.

The CTRI serves as the national clinical trial registry and is recognized by the World Health Organization's International Clinical Trials Registry Platform (ICTRP). Prospective registration of clinical trials has become an important mechanism for reducing publication bias, improving transparency, and ensuring public availability of essential study information.

The CTRI requires registration of key trial details, including:

- Study objectives
- Primary and secondary outcomes
- Intervention information
- Sponsor details
- Eligibility criteria
- Ethics approval information

The introduction of CTRI represented a major advancement in clinical research transparency and aligned India with global best practices in trial registration (Pillamarapu et al., 2019).

1.6 New Drugs and Clinical Trials Rules (NDCTR), 2019

Recognizing the need for a modern and comprehensive regulatory framework, the Government of India introduced the New Drugs and Clinical Trials Rules (NDCTR), 2019. These rules replaced several provisions of Schedule Y and established a more structured approach to clinical trial regulation.

Key objectives of NDCTR 2019 included:

- Accelerating approval timelines
- Strengthening participant protection
- Enhancing transparency
- Improving regulatory efficiency
- Supporting innovation
- Facilitating clinical research growth

The NDCTR introduced provisions related to:

- Clinical trial approvals
- Ethics Committee registration
- Compensation for trial-related injuries
- Academic clinical trials
- Biomedical and health research
- Accelerated approval pathways

The new framework significantly improved regulatory predictability and aligned India's clinical research environment with international regulatory expectations (Mahajan, 2020; Bhatt, 2021).

Table 1. Major Milestones in the Evolution of Clinical Trial Regulation in India

Year	Regulatory Milestone	Significance
1940	Drugs and Cosmetics Act	Foundation of pharmaceutical regulation
1945	Drugs and Cosmetics Rules	Implementation framework
2005	Schedule Y Revision	Introduction of GCP-based regulation
2007	Establishment of CTRI	Improved transparency
2013	Participant Protection Reforms	Enhanced ethical oversight
2019	NDCTR 2019	Comprehensive regulatory modernization
2023	CRO Registration Requirements	Increased accountability
2026	NDCT Amendments	Streamlined approvals and oversight



Figure 1. Evolution of Clinical Trial Regulation in India

1.7 Current Landscape of Clinical Research in India

Today, India is recognized as an important contributor to global clinical research. The country participates in multinational studies across therapeutic areas including oncology, cardiology, infectious diseases, neurology, endocrinology, and rare diseases. The COVID-19 pandemic further demonstrated India's research capabilities through large-scale vaccine development and clinical evaluation programs.

Recent regulatory reforms, expanding digital infrastructure, increasing adoption of Good Clinical Practice standards, and growing emphasis on participant-centric research have strengthened India's position within the global clinical research ecosystem. Nevertheless, challenges related to infrastructure, workforce development, public trust, and regulatory capacity remain important considerations for future growth.

The next section examines the current regulatory framework governing clinical trials in India, including the roles and responsibilities of key regulatory authorities, investigators, sponsors, Ethics Committees, and Contract Research Organizations.

2. Regulatory Framework Governing Clinical Trials in India

2.1 Introduction

A robust regulatory framework is essential for ensuring that clinical trials are conducted ethically, scientifically, and transparently while safeguarding the rights, safety, and well-being of research participants. Regulatory oversight provides assurance that clinical evidence generated during trials is reliable, reproducible, and suitable for supporting regulatory decision-making regarding the approval of new drugs, biologics, vaccines, and medical devices.

India's clinical trial regulatory system has evolved considerably over the past two decades. The implementation of the New Drugs and Clinical Trials Rules (NDCTR), 2019 marked a significant milestone in regulatory modernization by introducing defined timelines, streamlined approval procedures, enhanced participant protection measures, and clearer responsibilities for stakeholders involved in clinical research. The framework seeks to balance scientific innovation with ethical responsibility while encouraging domestic and international investment in biomedical research (Mahajan, 2020; Bhatt, 2021).

The Indian regulatory system operates through collaboration among multiple institutions, including regulatory authorities, Ethics Committees, investigators, sponsors, and Contract Research Organizations (CROs). Each stakeholder plays a distinct role in ensuring compliance with legal, ethical, and scientific requirements.

2.2 Regulatory Authorities Governing Clinical Trials

Central Drugs Standard Control Organization (CDSCO)

The Central Drugs Standard Control Organization (CDSCO) serves as the national regulatory authority responsible for overseeing clinical trials, drug approvals, medical devices, and pharmaceutical regulation in India. CDSCO functions under the Ministry of Health and Family Welfare and is the primary agency responsible for implementing the provisions of the Drugs and Cosmetics Act and NDCTR 2019.

The key responsibilities of CDSCO include:

- Approval of clinical trial applications
- Authorization of new drugs
- Registration of Ethics Committees
- Inspection of clinical trial sites
- Monitoring compliance with regulations
- Enforcement of Good Clinical Practice (GCP)
- Oversight of pharmacovigilance activities

The organization plays a central role in maintaining the integrity and quality of clinical research conducted within the country (Bhatt, 2021).

Drug Controller General of India (DCGI)

The Drug Controller General of India (DCGI) is the head of CDSCO and serves as the Central Licensing Authority (CLA) for clinical trials and new drugs. The DCGI evaluates clinical trial applications and ensures that studies comply with applicable scientific, ethical, and regulatory requirements.

Major responsibilities of the DCGI include:

- Reviewing clinical trial protocols
- Granting regulatory approvals
- Evaluating safety data
- Monitoring serious adverse event reports
- Ensuring participant protection
- Facilitating innovation while maintaining safety standards

The DCGI acts as the primary decision-making authority in matters related to clinical trial approvals and regulatory compliance.



Figure 2. Regulatory Structure for Clinical Trial Governance in India

2.3 New Drugs and Clinical Trials Rules (NDCTR), 2019

The New Drugs and Clinical Trials Rules (NDCTR), 2019 constitute the principal legal framework governing clinical trials in India. These rules replaced several provisions previously contained within Schedule Y and introduced a modernized regulatory structure aligned with international standards.

The primary objectives of NDCTR 2019 are:

- Protection of participant rights and safety
- Promotion of ethical research conduct
- Acceleration of clinical trial approvals
- Encouragement of innovation
- Strengthening transparency
- Harmonization with international regulatory practices

The rules apply to:

- New drugs
- Investigational medicinal products
- Biologics
- Vaccines
- Academic clinical trials
- Biomedical and health research involving investigational products

NDCTR 2019 has significantly improved regulatory predictability and efficiency while enhancing accountability among stakeholders (Mahajan, 2020).

2.4 Categories of Clinical Trials

The regulatory framework recognizes several categories of clinical research.

Phase I Trials

Phase I trials represent the first administration of an investigational product in humans. These studies primarily evaluate:

- Safety
- Tolerability
- Pharmacokinetics
- Pharmacodynamics

They typically involve healthy volunteers and small participant populations.

Phase II Trials

Phase II studies evaluate preliminary efficacy while continuing to assess safety. These trials generally involve patients affected by the target condition and help determine optimal dosing strategies.

Phase III Trials

Phase III studies are large-scale investigations designed to confirm efficacy and monitor safety across diverse patient populations. Results from Phase III trials often form the basis for regulatory approval decisions.

Phase IV Trials

Phase IV studies occur after market authorization and focus on:

- Long-term safety
- Rare adverse events
- Real-world effectiveness
- Comparative effectiveness

Post-marketing surveillance plays an important role in ensuring ongoing patient safety.

2.5 Clinical Trial Approval Process

The approval process established under NDCTR 2019 aims to ensure scientific validity, ethical acceptability, and participant safety.

Step 1: Protocol Development

Sponsors develop a detailed clinical trial protocol that includes:

- Study objectives
- Safety monitoring plans
- Methodology
- Statistical analysis strategies
- Eligibility criteria

Step 2: Ethics Committee Review

The protocol is submitted to an Institutional Ethics Committee for ethical evaluation.

The committee assesses:

- Risk-benefit balance
- Participant recruitment plans
- Informed consent procedures
- Safety safeguards

Step 3: Regulatory Submission

The sponsor submits the application to CDSCO along with:

- Protocol documents
- Ethics Committee approval
- Investigator's brochure
- Investigator credentials
- Preclinical data

Step 4: Regulatory Review

Scientific experts evaluate the submission to determine whether:

- Risks are acceptable
- Participant protections are sufficient
- Scientific rationale is adequate

Step 5: Approval

Upon satisfactory review, the DCGI grants approval, permitting study initiation.

Figure 3. Clinical Trial Approval Process in India

2.6 Defined Regulatory Timelines

One of the most significant improvements introduced by NDCTR 2019 is the establishment of defined timelines for regulatory decision-making.

Benefits include:

- Faster approvals
- Improved predictability
- Reduced administrative burden
- Greater sponsor confidence
- Enhanced competitiveness

Defined review periods reduce uncertainty and facilitate efficient clinical development programs (Bhatt, 2021).

2.7 Responsibilities of Sponsors

Sponsors bear primary responsibility for initiating, managing, financing, and overseeing clinical trials.

Key responsibilities include:

Study Design

Sponsors must ensure scientifically valid study protocols and appropriate statistical methodologies.

Safety Monitoring

Sponsors are required to continuously monitor participant safety and promptly report serious adverse events.

Regulatory Compliance

Sponsors must comply with:

- NDCTR 2019
- Good Clinical Practice
- Ethics Committee requirements
- Pharmacovigilance regulations

Data Integrity

Accurate and reliable data collection systems must be maintained throughout the study lifecycle.

Failure to fulfill these responsibilities may result in regulatory sanctions or suspension of trial activities.

2.8 Responsibilities of Investigators

Investigators play a central role in protecting participants and ensuring protocol compliance.

Their responsibilities include:

- Obtaining informed consent
- Conducting study procedures
- Maintaining source documentation
- Reporting adverse events
- Ensuring participant welfare
- Maintaining confidentiality

Investigators must possess adequate qualifications, training, and experience relevant to the clinical trial being conducted.

2.9 Contract Research Organizations (CROs)

Contract Research Organizations (CROs) provide specialized services supporting clinical trial operations.

Typical CRO functions include:

- Project management
- Site monitoring
- Data management
- Statistical analysis
- Regulatory affairs support
- Pharmacovigilance activities

Recent regulatory reforms introduced mandatory CRO registration requirements to strengthen accountability and quality assurance within the clinical research sector.

The registration framework aims to ensure:

- Professional competence
- Operational transparency
- Regulatory compliance
- Consistent quality standards

2.10 Good Clinical Practice (GCP)

Good Clinical Practice (GCP) represents the international ethical and scientific quality standard governing clinical research involving human participants.

Core GCP principles include:

- Protection of participant rights
- Scientific validity
- Risk-benefit assessment
- Informed consent
- Data integrity
- Confidentiality
- Quality assurance

India's regulatory framework strongly emphasizes GCP compliance and aligns closely with International Council for Harmonisation (ICH) guidelines.

Table 2. Key Components of the Indian Clinical Trial Regulatory Framework

Component	Requirement
Regulatory Authority	CDSCO/DCGI
Governing Regulation	NDCTR 2019
Ethics Approval	Mandatory
Clinical Trial Registration	CTRI
Informed Consent	Mandatory
Audio-Visual Consent	Required in specific situations
SAE Reporting	Mandatory
Compensation	Mandatory
CRO Registration	Mandatory
GCP Compliance	Mandatory

2.11 International Harmonization

India has increasingly aligned its clinical trial regulations with international standards.

Key harmonization initiatives include:

- Adoption of ICH Good Clinical Practice principles
- Participation in WHO clinical trial initiatives
- Strengthening pharmacovigilance systems
- Enhancing transparency requirements
- Improving regulatory convergence

Such efforts facilitate international collaboration and improve global acceptance of clinical data generated within India.

3. Ethics Committees and Participant Protection

3.1 Introduction

Ethics forms the foundation of clinical research involving human participants. Regardless of scientific merit, a clinical trial cannot be justified unless it adequately protects the rights, dignity, safety, and well-being of research participants. Throughout the history of biomedical research, several unethical studies highlighted the need for strong ethical safeguards and independent oversight mechanisms. Consequently, international ethical frameworks such as the Declaration of Helsinki, Belmont Report, Good Clinical Practice (GCP) Guidelines, and CIOMS Ethical Guidelines established principles that continue to guide clinical research worldwide.

In India, participant protection has become a major regulatory priority, particularly following concerns raised during the rapid expansion of clinical trial activity between 2005 and 2013. Reports of inadequate informed consent, poor compensation practices, and insufficient oversight prompted regulatory reforms that significantly strengthened ethical review systems. The New Drugs and Clinical Trials Rules (NDCTR), 2019 introduced stricter requirements for Ethics Committee registration, informed consent procedures, safety monitoring, and compensation mechanisms (Ghooi, 2021; Nundy & Gulhati, 2020).

Ethics Committees serve as independent bodies responsible for ensuring that research involving human participants is conducted according to ethical principles and regulatory requirements. Their role is central to maintaining public trust and protecting vulnerable populations participating in clinical trials.

3.2 Ethical Principles Governing Clinical Research

Clinical research ethics is based upon several universally accepted principles.

Respect for Persons

Participants must be treated as autonomous individuals capable of making informed decisions regarding their participation in research. Respect for autonomy requires that participants receive complete and understandable information regarding the study before providing consent.

Special protections must be provided to vulnerable populations, including:

- Children
- Pregnant women
- Elderly individuals
- Economically disadvantaged populations
- Cognitively impaired individuals

Beneficence

Researchers are required to maximize potential benefits while minimizing risks to participants. Clinical trials should be designed to generate meaningful scientific knowledge while avoiding unnecessary harm.

Non-Maleficence

The principle of non-maleficence requires investigators to avoid causing harm. Potential risks must be carefully evaluated before initiating a study.

Justice

The principle of justice requires equitable distribution of research benefits and burdens. Participant selection should be fair and free from exploitation or discrimination.

These ethical principles form the basis for regulatory oversight and Ethics Committee review in India and internationally (CIOMS, 2021).

3.3 Role of Ethics Committees

Ethics Committees (ECs) function as independent bodies responsible for reviewing, approving, and monitoring biomedical research involving human participants.

The primary objectives of Ethics Committees are:

- Protect participant rights
- Ensure participant safety
- Evaluate ethical acceptability
- Monitor protocol compliance
- Review informed consent procedures
- Assess risk-benefit balance

Ethics Committees operate independently of sponsors and investigators to minimize conflicts of interest and ensure objective decision-making.

Under NDCTR 2019, no clinical trial can commence without prior approval from a registered Ethics Committee and CDSCO approval where applicable.



Figure 4. Ethics Committee Review Process

3.4 Composition of Ethics Committees

To ensure multidisciplinary evaluation of research proposals, Ethics Committees must include members from diverse professional backgrounds.

Typical membership includes:

- Chairperson (independent)
- Medical scientists
- Clinicians
- Legal expert
- Social scientist
- Ethicist
- Lay person/community representative
- Basic medical scientist

Diverse membership ensures comprehensive assessment of scientific, ethical, legal, and social aspects of clinical research.

Independence

The Chairperson should generally be independent of the institution conducting the research to reduce potential conflicts of interest and strengthen objectivity.

Quorum Requirements

Meetings require a minimum quorum representing scientific and non-scientific perspectives before decisions can be made.

Table 3. Typical Composition of an Ethics Committee

Member Category	Role
Chairperson	Independent leadership
Medical Scientist	Scientific evaluation
Clinician	Clinical expertise
Legal Expert	Regulatory compliance
Ethicist	Ethical assessment
Social Scientist	Community perspectives
Lay Person	Public representation
Basic Scientist	Methodological review

3.5 Registration and Accreditation of Ethics Committees

A major reform introduced in India was mandatory registration of Ethics Committees with CDSCO.

Registration aims to:

- Improve accountability
- Standardize review procedures
- Strengthen participant protection
- Facilitate regulatory oversight

Registered Ethics Committees are required to:

- Maintain standard operating procedures
- Document meeting proceedings
- Retain study records
- Conduct continuing review
- Report non-compliance

Increasing emphasis is also being placed on accreditation programs to enhance quality and consistency among Ethics Committees.

Accreditation initiatives encourage:

- Training and capacity building
- Standardized review processes
- Continuous quality improvement

3.6 Informed Consent Process

Informed consent represents one of the most important ethical requirements in clinical research.

It is a process through which participants voluntarily agree to participate after receiving adequate information regarding:

- Study objectives
- Procedures
- Risks
- Benefits
- Alternatives
- Confidentiality protections
- Compensation arrangements
- Right to withdraw

Consent must be:

- Voluntary
- Informed
- Comprehensible
- Documented

Participants should have sufficient opportunity to ask questions and consider their decision before enrollment.

Essential Elements of Informed Consent

Researchers must explain:

1. Purpose of the study
2. Expected duration
3. Experimental procedures
4. Potential risks
5. Potential benefits
6. Alternative treatments
7. Confidentiality measures
8. Compensation provisions
9. Contact information
10. Voluntary participation rights

Failure to obtain valid informed consent constitutes a serious ethical violation.



Figure 5. Informed Consent Process

3.7 Audio-Visual Recording of Consent

India became one of the first countries to introduce mandatory audio-visual recording of informed consent in specific clinical trial situations.

Objectives include:

- Improving transparency
- Preventing coercion
- Documenting participant understanding
- Strengthening accountability

Audio-visual recording is particularly important in:

- Vulnerable populations
- High-risk studies
- Regulatory investigations

Although implementation may increase administrative requirements, it significantly strengthens participant protection and public confidence in clinical research.

3.8 Protection of Vulnerable Populations

Certain groups may face increased risk of exploitation or coercion during research participation.

Examples include:

- Children
- Pregnant women
- Prisoners
- Economically disadvantaged individuals
- Individuals with cognitive impairment

Ethics Committees must ensure that:

- Participation is justified scientifically
- Risks are minimized
- Additional safeguards are implemented
- Consent procedures are appropriate

Research involving vulnerable populations requires careful ethical scrutiny and enhanced monitoring.

3.9 Safety Monitoring and Serious Adverse Event Reporting

Participant safety remains the highest priority throughout the conduct of a clinical trial.

Investigators and sponsors are required to continuously monitor participants for adverse events.

Serious Adverse Events (SAEs)

An SAE includes events that:

- Result in death
- Are life-threatening
- Require hospitalization
- Cause significant disability
- Result in congenital anomalies

Prompt reporting of SAEs to:

- Sponsor
- Ethics Committee
- CDSCO

is mandatory under NDCTR 2019.

Ethics Committees play a critical role in reviewing SAE reports and determining whether additional participant protections are necessary.

4. Clinical Trial Approval and Registration System

4.1 Introduction

A transparent, efficient, and scientifically rigorous approval and registration system is essential for maintaining public trust and ensuring the ethical conduct of clinical research. Regulatory approval and trial registration are critical components of clinical trial governance because they ensure that research studies meet scientific, ethical, and legal requirements before participant enrollment begins. These mechanisms protect participants from unnecessary risks, promote accountability among researchers and sponsors, and improve transparency within the clinical research ecosystem.

India has made significant progress in strengthening its approval and registration framework through the implementation of the New Drugs and Clinical Trials Rules (NDCTR), 2019 and the expansion of the Clinical Trial Registry–India (CTRI). These reforms have enhanced transparency, reduced approval delays, improved participant protection, and aligned Indian practices with international standards such as those recommended by the World Health Organization (WHO) and International Council of Medical Journal Editors (ICMJE) (Zarin et al., 2016; Bhide et al., 2022).

4.2 Importance of Clinical Trial Approval

Clinical trial approval serves as the formal regulatory authorization permitting a sponsor or investigator to initiate a clinical study involving human participants.

The approval process ensures that:

- The scientific rationale is valid.
- Participant risks are minimized.
- Ethical principles are respected.
- Safety monitoring procedures are adequate.
- Data generated will be scientifically meaningful.

Without regulatory approval, clinical trials cannot legally proceed.

Approval systems are designed to balance two important objectives:

1. Protecting participants from harm.
2. Facilitating scientific innovation and medical advancement.

Effective approval mechanisms contribute to public confidence in healthcare research and regulatory decision-making.

4.3 Clinical Trial Application Process

Under NDCTR 2019, sponsors must submit detailed applications to CDSCO before initiating clinical trials involving investigational products.

Components of an Application

A typical application includes:

- Clinical trial protocol
- Investigator's Brochure
- Preclinical study reports
- Chemistry, manufacturing, and control (CMC) information
- Investigator qualifications
- Ethics Committee approval
- Informed consent documents
- Insurance and compensation information

The submission package must provide sufficient evidence demonstrating that the proposed study is scientifically justified and ethically acceptable.

4.4 Scientific Review Process

The scientific review process evaluates whether a proposed study is methodologically sound and capable of generating reliable evidence.

Regulatory reviewers assess:

Scientific Validity

- Study objectives
- Research questions
- Endpoints
- Statistical methodology

Risk-Benefit Assessment

Potential benefits must outweigh foreseeable risks.

Participant Protection Measures

Reviewers evaluate:

- Inclusion and exclusion criteria
- Monitoring procedures
- Safety management plans

Investigator Competence

Investigators must possess appropriate qualifications, training, and experience.

Scientific review ensures that participants are not exposed to unnecessary risks through poorly designed studies.

4.5 Regulatory Timelines under NDCTR 2019

One of the major innovations introduced by NDCTR 2019 is the establishment of defined regulatory timelines.

Benefits include:

- Faster approvals
- Increased predictability
- Reduced administrative burden
- Improved global competitiveness

Defined timelines help sponsors plan clinical development programs more effectively while maintaining regulatory rigor.

The introduction of deemed approval provisions in certain circumstances has further improved regulatory efficiency.

4.6 Ethics Committee Approval Requirements

Before obtaining regulatory approval, studies must generally receive clearance from a registered Ethics Committee.

The Ethics Committee evaluates:

- Ethical acceptability
- Participant safety
- Informed consent procedures
- Recruitment strategies
- Confidentiality protections

Ethics Committee approval serves as an independent safeguard against unethical research practices.

Both Ethics Committee approval and regulatory authorization are necessary components of the approval process.

4.7 Clinical Trial Registration

Concept and Importance

Clinical trial registration involves publicly recording essential information regarding a study before participant enrollment begins.

Registration serves several important purposes:

- Enhances transparency
- Reduces publication bias
- Prevents selective reporting
- Facilitates public access to research information
- Supports research accountability

International organizations increasingly require prospective registration as a prerequisite for publication and regulatory acceptance.

4.8 Clinical Trial Registry–India (CTRI)

The Clinical Trial Registry–India (CTRI) was established in 2007 and is hosted by the Indian Council of Medical Research (ICMR).

The CTRI is recognized by the World Health Organization's International Clinical Trials Registry Platform (ICTRP).

Objectives of CTRI

The registry aims to:

- Improve transparency
- Increase public trust
- Enhance research accountability
- Promote ethical conduct
- Facilitate evidence synthesis

Registration in CTRI is mandatory for clinical trials conducted in India.

Table 4. Information Required for CTRI Registration

Category	Information Required
Administrative	Title, sponsor, investigator
Scientific	Objectives, design, intervention
Participants	Eligibility criteria, sample size
Outcomes	Primary and secondary endpoints

Ethics	EC approval details
Status	Recruitment and completion status
Contact Information	Investigator contact details

5. Recent Regulatory Reforms in India (2020–2026)

5.1 Introduction

The period between 2020 and 2026 represents one of the most transformative phases in the history of clinical trial regulation in India. The implementation of the New Drugs and Clinical Trials Rules (NDCTR), 2019 provided a strong foundation for modernization; however, several additional reforms were introduced in response to evolving scientific, technological, and public health challenges. The COVID-19 pandemic accelerated the need for regulatory flexibility, digital transformation, rapid approvals, and innovative clinical trial methodologies.

Regulatory authorities worldwide faced unprecedented pressure to facilitate rapid development of vaccines, therapeutics, and diagnostics while maintaining rigorous standards of participant safety and scientific integrity. India responded by strengthening regulatory processes, expanding digital infrastructure, introducing streamlined approval pathways, enhancing transparency, and promoting greater accountability among stakeholders (Mahajan, 2020; Bhatt, 2021).

These reforms have significantly improved India's attractiveness as a destination for clinical research while strengthening participant protection and regulatory oversight.

5.2 Impact of COVID-19 on Clinical Trial Regulation

The COVID-19 pandemic fundamentally altered the global clinical research landscape. Traditional trial models faced significant challenges due to lockdowns, travel restrictions, healthcare system pressures, and participant safety concerns.

Key regulatory priorities during the pandemic included:

- Accelerated evaluation of vaccines and therapeutics
- Protection of participants and research staff
- Continuity of ongoing clinical trials
- Remote monitoring and virtual assessments
- Digital regulatory processes

Indian regulators introduced several temporary and permanent measures to address these challenges.

Key Regulatory Responses

- Expedited review procedures
- Online submissions
- Virtual meetings
- Remote monitoring approaches
- Flexible protocol implementation

These initiatives demonstrated the ability of regulatory systems to adapt rapidly during public health emergencies (Keesara et al., 2020; Whitelaw et al., 2020).

5.3 Digital Transformation of Regulatory Processes

One of the most important developments during this period was the expansion of digital regulatory infrastructure.

Electronic Submission Systems

CDSCO increasingly adopted electronic platforms for:

- Clinical trial applications
- Regulatory correspondence
- Safety reporting
- Documentation management

Digital submissions reduced administrative burdens, improved efficiency, and enhanced transparency.

Virtual Regulatory Interactions

The pandemic accelerated adoption of:

- Virtual meetings
- Online consultations
- Electronic document review

These innovations improved accessibility and reduced delays associated with traditional paper-based systems.

Benefits of Digitalization

- Faster processing
- Reduced paperwork
- Improved transparency
- Better record management
- Enhanced stakeholder communication

Digital transformation is expected to remain a central feature of India's future regulatory strategy.

Figure 6. Timeline of Major Regulatory Reforms (2020–2026)

5.4 Accelerated Approval Pathways

Rapid access to innovative therapies became particularly important during the COVID-19 pandemic.

Objectives of Accelerated Approvals

- Address unmet medical needs
- Improve patient access
- Support innovation
- Reduce development timelines

Regulators introduced mechanisms enabling faster review of products demonstrating substantial potential public health benefits.

These pathways include:

- Priority review
- Conditional approvals
- Accelerated assessments

While accelerating access, regulators continued to require robust evidence regarding safety and efficacy.

Such approaches aligned India with international regulatory trends observed in the United States, European Union, Japan, and other major jurisdictions.

5.5 Risk-Based Monitoring Approaches

Traditional clinical trial monitoring often relies heavily on extensive on-site inspections and source data verification.

Recent reforms increasingly emphasize risk-based monitoring methodologies.

Principles of Risk-Based Monitoring

Resources are focused on:

- Critical data elements
- High-risk study activities
- Participant safety indicators
- Protocol compliance

Benefits include:

- Improved efficiency
- Reduced costs
- Better allocation of resources
- Enhanced quality management

Risk-based approaches are consistent with evolving International Council for Harmonisation (ICH) recommendations and global best practices.

5.6 Strengthening Ethics Committee Oversight

Regulatory authorities have continued efforts to improve the quality and consistency of Ethics Committee review.

Key Improvements

- Enhanced registration requirements
- Greater documentation standards
- Increased monitoring activities
- Capacity-building initiatives
- Standard operating procedure development

Ethics Committees are increasingly expected to demonstrate:

- Independence
- Competence
- Transparency
- Continuous oversight capabilities

These measures strengthen participant protection and promote ethical excellence within clinical research.

Table 5. Major Clinical Trial Regulatory Reforms in India (2020–2026)

Year	Reform	Expected Impact
2020	COVID-19 Emergency Measures	Research continuity
2021	Digital Submission Expansion	Faster approvals
2022	Risk-Based Monitoring Adoption	Improved efficiency
2023	CRO Registration Requirements	Enhanced accountability
2024	Strengthened Ethics Oversight	Better participant protection
2025	Digital Health Integration	Improved innovation
2026	NDCT Amendment Rules	Streamlined regulation

6. Challenges in Clinical Trial Regulation in India

6.1 Introduction

Despite substantial regulatory reforms and significant growth in clinical research activity, India continues to face several challenges that affect the efficiency, quality, and global competitiveness of its clinical trial ecosystem. The implementation of NDCTR 2019, enhanced ethical oversight, mandatory trial registration, and digital regulatory initiatives have strengthened governance; however, operational, ethical, infrastructural, and societal barriers continue to influence clinical trial conduct.

The challenges are multifactorial and involve interactions among regulators, sponsors, investigators, Ethics Committees, healthcare institutions, participants, and policymakers. Addressing these issues is essential for ensuring sustainable growth of clinical research while maintaining participant safety and scientific integrity. Although India possesses considerable advantages, including a large patient population, cost-efficient research infrastructure, and increasing regulatory maturity, overcoming persistent barriers remains critical for achieving global leadership in clinical research (Bhatt, 2021; Mahajan, 2020).

6.2 Regulatory Challenges

Regulatory Complexity

Clinical trial regulation involves multiple stakeholders and extensive documentation requirements. Sponsors must comply with CDSCO regulations, Ethics Committee requirements, Good Clinical Practice guidelines, pharmacovigilance obligations, and data management standards.

Although NDCTR 2019 simplified many processes, investigators and sponsors continue to face administrative burdens associated with:

- Regulatory submissions
- Ethics approvals
- Safety reporting
- Documentation requirements
- Inspection preparedness

Smaller academic institutions often lack dedicated regulatory affairs personnel, making compliance more challenging.

Regulatory Capacity Constraints

The increasing volume of clinical trial applications requires adequate numbers of trained reviewers and inspectors. Limited regulatory resources may contribute to delays in application review, inspections, and post-approval monitoring activities.

As clinical research increasingly incorporates advanced technologies such as artificial intelligence, digital therapeutics, and genomic medicine, regulators require specialized expertise to evaluate complex scientific and ethical issues.

6.3 Ethical Challenges

Variability in Ethics Committee Performance

Although Ethics Committees are mandatory and registered with CDSCO, substantial variability exists in terms of:

- Expertise
- Infrastructure
- Resources
- Training
- Review quality

Some committees possess extensive experience and robust operating procedures, whereas others face limitations that may affect consistency of ethical review.

Conflict of Interest

Potential conflicts of interest may arise among:

- Investigators
- Sponsors
- Institutions
- Ethics Committee members

Financial incentives and institutional pressures can influence decision-making if adequate safeguards are not implemented.

Emerging Ethical Issues

Technological innovation has introduced new ethical concerns involving:

- Artificial intelligence
- Big data analytics

- Digital health platforms
- Real-world data collection
- Genetic testing

Traditional ethical frameworks may require adaptation to address these emerging challenges effectively (Ghooi, 2021).

6.4 Participant Recruitment Challenges

Participant recruitment remains one of the most significant barriers to successful clinical trial completion.

Limited Public Awareness

Many individuals possess limited understanding of:

- Clinical trial objectives
- Participant rights
- Research benefits
- Safety protections

This lack of awareness contributes to hesitancy and reduced participation rates.

Cultural and Social Factors

Several cultural factors may influence recruitment:

- Family decision-making
- Traditional beliefs
- Fear of experimentation
- Misinformation regarding research

Historical controversies have also affected public perceptions of clinical trials in some communities (Nundy & Gulhati, 2020).

Recruitment Competition

Increasing numbers of clinical trials often compete for similar participant populations, particularly in specialized therapeutic areas.

Consequences include:

- Extended recruitment periods
- Increased costs
- Delayed study completion

Effective participant engagement strategies are therefore essential for successful trial implementation.

7. Future Prospects and Emerging Trends (2026–2035)

7.1 Introduction

The future of clinical trial regulation in India will be shaped by rapid technological innovation, digital transformation, increasing globalization of healthcare research, and evolving participant expectations. While significant regulatory reforms have strengthened India's clinical research ecosystem, the next decade is expected to witness a transition from traditional trial models toward more patient-centric, technology-enabled, and data-driven approaches.

Globally, regulatory agencies are increasingly embracing innovative methodologies such as artificial intelligence (AI), decentralized clinical trials (DCTs), real-world evidence (RWE), precision medicine, adaptive trial designs, and digital health technologies. These innovations have the potential to improve efficiency, reduce costs, accelerate drug development, and enhance participant engagement. India is well-positioned to capitalize on these opportunities due to its large patient population, expanding healthcare infrastructure, rapidly growing digital ecosystem, and strong pharmaceutical industry (Topol, 2023; Van Norman, 2021).

However, successful implementation will require adaptive regulatory frameworks capable of balancing innovation with participant protection, ethical oversight, data integrity, and public trust.

7.2 Artificial Intelligence in Clinical Research

Artificial Intelligence is expected to become one of the most transformative technologies in clinical research.

AI systems can analyze large datasets, identify patterns, optimize decision-making, and automate complex processes that traditionally required extensive human effort.

Applications of AI in Clinical Trials

AI can support:

- Patient recruitment
- Site selection
- Protocol optimization
- Data monitoring
- Safety surveillance
- Outcome prediction
- Pharmacovigilance

Machine learning algorithms can identify eligible participants more efficiently by analyzing electronic health records and healthcare databases. Such approaches may significantly reduce recruitment timelines and improve enrollment efficiency.

Benefits

Potential benefits include:

- Faster trial execution
- Improved accuracy
- Reduced costs
- Enhanced data quality
- Better patient matching

Regulatory Challenges

Despite its advantages, AI introduces important regulatory concerns:

- Algorithm transparency
- Explainability
- Bias and fairness
- Accountability
- Data privacy

Future regulatory frameworks in India will likely include dedicated guidance for validation and governance of AI-based clinical research tools (Topol, 2023; Krishnan et al., 2023).

7.3 Decentralized Clinical Trials (DCTs)

Decentralized Clinical Trials represent a major evolution in clinical research methodology.

Traditional trials require participants to travel repeatedly to research sites. DCTs utilize digital technologies that allow many trial activities to occur remotely.

Components of DCTs

Common elements include:

- Telemedicine consultations
- Electronic informed consent
- Remote monitoring
- Wearable devices
- Home healthcare visits
- Mobile applications

Advantages

Benefits include:

- Reduced participant burden
- Improved accessibility
- Increased diversity
- Better retention
- Faster recruitment

For a geographically diverse country such as India, DCTs could significantly expand participation among rural and underserved populations.

Regulatory Considerations

Challenges requiring regulatory attention include:

- Participant identity verification
- Data security

- Device validation
- Remote safety monitoring

Future regulations are expected to incorporate specific provisions governing decentralized research methodologies (Van Norman, 2021; Inan et al., 2020).

7.4 Real-World Evidence (RWE)

Real-World Evidence refers to clinical evidence derived from data collected outside traditional randomized clinical trials.

Sources of Real-World Data

Examples include:

- Electronic health records
- Insurance claims databases
- Patient registries
- Mobile health applications
- Wearable sensors
- Patient-reported outcomes

Importance of RWE

RWE can support:

- Post-marketing surveillance
- Long-term safety assessment
- Comparative effectiveness studies
- Rare disease research
- Regulatory decision-making

Regulatory agencies worldwide increasingly recognize the value of RWE as a complementary source of evidence.

Opportunities for India

India's rapidly expanding digital health ecosystem, including initiatives such as the Ayushman Bharat Digital Mission, creates significant opportunities for large-scale RWE generation.

Future regulatory frameworks may increasingly incorporate RWE into approval, monitoring, and pharmacovigilance processes (Sherman et al., 2016; Eichler et al., 2021).

Figure 7. Future Clinical Research Ecosystem in India (2026–2035)

7.5 Precision Medicine and Personalized Healthcare

Precision medicine seeks to tailor treatment strategies according to individual characteristics including:

- Genetic factors
- Biomarkers
- Environmental influences
- Lifestyle variables

Advances in genomics and bioinformatics have accelerated development of personalized therapeutic approaches.

Impact on Clinical Trials

Precision medicine is transforming study design through:

- Biomarker-driven studies
- Basket trials
- Umbrella trials
- Adaptive trial designs

These methodologies improve efficiency by targeting therapies to patient populations most likely to benefit.

Opportunities for India

India's genetic diversity provides unique opportunities for:

- Population-specific genomic research
- Biomarker discovery
- Personalized therapeutics development

Future regulatory frameworks must adapt to support these increasingly sophisticated research models (Collins & Varmus, 2015; Collins et al., 2021).

Conclusion

Clinical trial regulation in India has evolved considerably from the early provisions of the Drugs and Cosmetics Act, 1940 to the comprehensive regulatory framework established under the New Drugs and Clinical Trials Rules (NDCTR), 2019. Over the past two decades, India has implemented significant reforms aimed at improving participant protection, enhancing transparency, strengthening ethical oversight, and aligning national regulations with international standards.

The establishment of the Clinical Trial Registry–India (CTRI), mandatory Ethics Committee registration, strengthened compensation mechanisms, risk-based monitoring approaches, and digital regulatory initiatives have collectively transformed India's clinical research landscape. Recent reforms introduced between 2020 and 2026 further accelerated modernization through digitalization, CRO registration, expedited review pathways, and increasing adoption of innovative research methodologies.

Despite these achievements, several challenges continue to affect the conduct and oversight of clinical research. Regulatory complexity, infrastructure disparities, participant recruitment difficulties, workforce shortages, data

integrity concerns, and public trust issues remain important barriers to growth. Addressing these challenges requires coordinated efforts involving regulators, researchers, sponsors, healthcare institutions, and policymakers.

Emerging technologies such as artificial intelligence, decentralized clinical trials, real-world evidence generation, precision medicine, and digital health platforms offer unprecedented opportunities to improve efficiency, participant engagement, and evidence generation. However, these innovations also introduce new ethical, operational, and regulatory challenges that necessitate adaptive governance frameworks.

India possesses significant strengths, including a large patient population, genetic diversity, a growing pharmaceutical industry, and expanding digital infrastructure. Through continued regulatory modernization, investment in research capacity, workforce development, international collaboration, and participant-centered approaches, India is well positioned to become a global leader in clinical research and biomedical innovation over the coming decade.

The future success of India's clinical trial ecosystem will depend upon its ability to balance innovation with participant protection, scientific rigor, transparency, and ethical responsibility. With sustained commitment to these principles, India can play a pivotal role in advancing global healthcare research and improving patient outcomes worldwide.

Abbreviations

Abbreviation	**Full Form**
AI	Artificial Intelligence
CDSCO	Central Drugs Standard Control Organization
CIOMS	Council for International Organizations of Medical Sciences
CRO	Contract Research Organization
CTRI	Clinical Trial Registry–India
DCGI	Drug Controller General of India
DCT	Decentralized Clinical Trial
EC	Ethics Committee
EMA	European Medicines Agency
FDA	Food and Drug Administration
GCP	Good Clinical Practice
ICH	International Council for Harmonisation
ICMJE	International Committee of Medical Journal Editors
ICMR	Indian Council of Medical Research
ICTRP	International Clinical Trials Registry Platform
NDCTR	New Drugs and Clinical Trials Rules
RWE	Real-World Evidence
SAE	Serious Adverse Event
WHO	World Health Organization

References

1. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71.
DOI: https://doi.org/10.1136/bmj.n71
2. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Journal of Clinical Epidemiology, 134, 178–189.
DOI: https://doi.org/10.1016/j.jclinepi.2021.03.001
3. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 statement. PLOS Medicine, 18(3), e1003583.
DOI: https://doi.org/10.1371/journal.pmed.1003583
4. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 statement. Systematic Reviews, 10, 89.
DOI: https://doi.org/10.1186/s13643-021-01626-4
5. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 statement. International Journal of Surgery, 88, 105906.
DOI: https://doi.org/10.1016/j.ijsu.2021.105906
6. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56.
DOI: https://doi.org/10.1038/s41591-018-0300-7
7. Wynants, L., Van Calster, B., Collins, G. S., et al. (2020). Prediction models for diagnosis and prognosis of COVID-19. BMJ, 369, m1328.
DOI: https://doi.org/10.1136/bmj.m1328
8. Krishnan, G., et al. (2023). Artificial intelligence in clinical medicine: Catalyzing a sustainable global healthcare paradigm. Frontiers in Medicine, 10.
DOI: https://doi.org/10.3389/fmed.2023.1227091
9. Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. New England Journal of Medicine, 372(9), 793–795.
DOI: https://doi.org/10.1056/NEJMp1500523
10. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., et al. (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine, 6(7), e1000097.
DOI: https://doi.org/10.1371/journal.pmed.1000097
11. Liberati, A., Altman, D. G., Tetzlaff, J., et al. (2009). The PRISMA Statement for reporting systematic reviews and meta-analyses. BMJ, 339, b2700.
DOI: https://doi.org/10.1136/bmj.b2700
12. Liberati, A., Altman, D. G., Tetzlaff, J., et al. (2009). Explanation and elaboration of PRISMA. Journal of Clinical Epidemiology, 62(10), e1–e34.
DOI: https://doi.org/10.1016/j.jclinepi.2009.06.006
13. Endler, M., Al-Haidari, T., Benedetti, G., et al. (2022). Telemedicine and decentralized care approaches. The Lancet, 400, 670–679.
DOI: https://doi.org/10.1016/S0140-6736(22)01240-1
14. Dembrower, K., et al. (2023). Artificial intelligence in screening and diagnostics. The Lancet Digital Health, 5, E703–E711.
DOI: https://doi.org/10.1016/S2589-7500(23)00160-0
15. Ng, A. Y., et al. (2023). Artificial intelligence in medicine and healthcare delivery. Nature Medicine, 29, 3044–3049.
DOI: https://doi.org/10.1038/s41591-023-02679-z

16.Kim, J., et al. (2025). Artificial intelligence tools in supporting healthcare professionals for tailored patient care. NPJ Digital Medicine.
DOI: https://doi.org/10.1038/s41746-025-01604-3
17.Mohajer-Bastami, A., et al. (2025). Artificial intelligence in healthcare: Applications, challenges and future directions. Frontiers in Digital Health.
DOI: https://doi.org/10.3389/fdgth.2025.1644041
18.Angus, D. C. (2025). AI, Health, and Health Care Today and Tomorrow. JAMA.
DOI: https://doi.org/10.1001/jama.2025.10283
19.Quer, G., et al. (2024). The potential for large language models to transform cardiovascular medicine. The Lancet Digital Health.
DOI: https://doi.org/10.1016/S2589-7500(24)00151-1
20.Kumah, E., et al. (2025). Artificial intelligence in healthcare and its implications for patient-centered care. International Journal of Health Economics and Management.
DOI: https://doi.org/10.1186/s12982-025-00924-9
21.Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56.
DOI: https://doi.org/10.1038/s41591-018-0300-7
22.Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. New England Journal of Medicine, 372(9), 793–795.
DOI: https://doi.org/10.1056/NEJMp1500523
23.Wynants, L., Van Calster, B., Collins, G. S., et al. (2020). Prediction models for diagnosis and prognosis of COVID-19 infection: Systematic review and critical appraisal. BMJ, 369, m1328.
DOI: https://doi.org/10.1136/bmj.m1328
24.Zarin, D. A., Tse, T., Williams, R. J., & Carr, S. (2016). Trial reporting in ClinicalTrials.gov — The final rule. New England Journal of Medicine, 375(20), 1998–2004.
DOI: https://doi.org/10.1056/NEJMsr1611785
25.Pillamarapu, M., Mohan, A., & Saberwal, G. (2019). An analysis of deficiencies in the data of interventional drug trials registered with Clinical Trials Registry–India. Trials, 20, 535.
DOI: https://doi.org/10.1186/s13063-019-3645-7
26.Borana, R., & Bhaumik, S. (2022). Compliance with ICMJE policy on individual participant data sharing in clinical trial registries. Perspectives in Clinical Research, 13(4), 214–219.
DOI: https://doi.org/10.4103/picr.picr_132_21
27.Bhide, A., Shah, P., & Kulkarni, R. (2022). Compliance trends in clinical trial registration in India. Perspectives in Clinical Research, 13(2), 87–95.
DOI: https://doi.org/10.4103/picr.picr_89_21
28.Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., et al. (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses. PLoS Medicine, 6(7), e1000097.
DOI: https://doi.org/10.1371/journal.pmed.1000097
29.Liberati, A., Altman, D. G., Tetzlaff, J., et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses. BMJ, 339, b2700.
DOI: https://doi.org/10.1136/bmj.b2700
30.Liberati, A., Altman, D. G., Tetzlaff, J., et al. (2009). PRISMA explanation and elaboration. Journal of Clinical Epidemiology, 62(10), e1–e34.
DOI: https://doi.org/10.1016/j.jclinepi.2009.06.006
31.De Angelis, C., Drazen, J. M., Frizelle, F. A., et al. (2004). Clinical trial registration: A statement from the ICMJE. New England Journal of Medicine, 351(12), 1250–1251.
DOI: https://doi.org/10.1056/NEJMe048225
32.Viergever, R. F., & Li, K. (2015). Trends in global clinical trial registration. BMJ Open, 5(9), e008932.
DOI: https://doi.org/10.1136/bmjopen-2015-008932

33.Huser, V., & Cimino, J. J. (2013). Evaluating adherence to registration and reporting policies. Journal of Biomedical Informatics, 46(6), 1072–1080.
DOI: https://doi.org/10.1016/j.jbi.2013.08.002
34.Chan, A. W., Song, F., Vickers, A., et al. (2014). Increasing value and reducing waste in biomedical research. Lancet, 383(9912), 257–266.
DOI: https://doi.org/10.1016/S0140-6736(13)62229-1
35.Ioannidis, J. P. A. (2016). Why most clinical research is not useful. PLoS Medicine, 13(6), e1002049.
DOI: https://doi.org/10.1371/journal.pmed.1002049
36.Eichler, H. G., Pignatti, F., Schwarzer-Daum, B., et al. (2021). Randomized controlled trials versus real-world evidence. Nature Reviews Drug Discovery, 20, 255–256.
DOI: https://doi.org/10.1038/d41573-021-00014-3
37.Sherman, R. E., Anderson, S. A., Dal Pan, G. J., et al. (2016). Real-world evidence — What is it and what can it tell us? New England Journal of Medicine, 375(23), 2293–2297.
DOI: https://doi.org/10.1056/NEJMsb1609216
38.Coravos, A., Khozin, S., & Mandl, K. D. (2019). Developing and adopting safe digital biomarkers. NPJ Digital Medicine, 2, 14.
DOI: https://doi.org/10.1038/s41746-019-0090-4
39.Izmailova, E. S., Ellis, R., & Benko, C. (2020). Remote monitoring in clinical trials during COVID-19. Clinical and Translational Science, 13(5), 838–841.
DOI: https://doi.org/10.1111/cts.12877
40.Kadakia, K. T., Beckman, A. L., Ross, J. S., & Krumholz, H. M. (2016). Leveraging real-world data for clinical research. JAMA, 316(20), 2147–2148.
DOI: https://doi.org/10.1001/jama.2016.12260
41.Harrer, S., Shah, P., Antony, B., & Hu, J. (2019). Artificial intelligence for clinical trial design. Trends in Pharmacological Sciences, 40(8), 577–591.
DOI: https://doi.org/10.1016/j.tips.2019.05.005
42.Park, J. J. H., Harari, O., Dron, L., et al. (2021). An overview of platform trials. Nature Reviews Drug Discovery, 20(7), 533–552.
DOI: https://doi.org/10.1038/s41573-021-00176-6
43.Angus, D. C. (2020). Optimizing the trade-off between learning and doing in a pandemic. JAMA, 323(19), 1895–1896.
DOI: https://doi.org/10.1001/jama.2020.4984
44.Eichler, H. G., Cavaleri, M., Enzmann, H., et al. (2020). Clinical trials for COVID-19: Can we better use the short window of opportunity? Clinical Pharmacology & Therapeutics, 108(4), 730–733.
DOI: https://doi.org/10.1002/cpt.1891
45.Getz, K. A., Campo, R. A., & Kaitin, K. I. (2020). Variability in protocol design complexity. Therapeutic Innovation & Regulatory Science, 54(4), 784–792.
DOI: https://doi.org/10.1007/s43441-019-00079-9
46.Mahajan, R. (2020). Clinical trials in India: Past, present and future. Indian Journal of Pharmacology, 52(3), 157–159.
DOI: https://doi.org/10.4103/ijp.IJP_205_20
47.Bhatt, A. (2021). Clinical trials in India: Opportunities and challenges. Perspectives in Clinical Research, 12(2), 63–67.
DOI: https://doi.org/10.4103/picr.picr_145_20
48.Ghooi, R. B. (2021). Ethics committees and clinical trials in India. Perspectives in Clinical Research, 12(1), 1–4.
DOI: https://doi.org/10.4103/picr.picr_220_20
49.Dal-Ré, R., Mahillo-Fernández, I., & Caplan, A. L. (2021). Ethics review during pandemics. BMJ Open, 11(2), e043724.
DOI: https://doi.org/10.1136/bmjopen-2020-043724

50.London, A. J., & Kimmelman, J. (2020). Against pandemic research exceptionalism. Science, 368(6490), 476–477.
DOI: https://doi.org/10.1126/science.abc1731
51.Keesara, S., Jonas, A., & Schulman, K. (2020). Covid-19 and digital transformation of healthcare. New England Journal of Medicine, 382(23), e82.
DOI: https://doi.org/10.1056/NEJMp2005835
52.Whitelaw, S., Mamas, M. A., Topol, E., & Van Spall, H. (2020). Applications of digital technology in COVID-19. Lancet Digital Health, 2(8), e435–e440.
DOI: https://doi.org/10.1016/S2589-7500(20)30142-4
53.Izmailova, E. S., Wagner, J. A., & Perakslis, E. D. (2018). Wearable devices in clinical trials. Clinical Pharmacology & Therapeutics, 104(1), 12–14.
DOI: https://doi.org/10.1002/cpt.1054
54.Rosa, C., Campbell, A. N. C., Miele, G. M., Brunner, M., & Winstanley, E. L. (2021). Using e-consent in clinical research. Contemporary Clinical Trials Communications, 19, 100639.
DOI: https://doi.org/10.1016/j.conctc.2020.100639
55.Khozin, S., Coravos, A., & Goldsack, J. C. (2020). Digital health technologies for clinical trials. Nature Biotechnology, 38(10), 1127–1129.
DOI: https://doi.org/10.1038/s41587-020-0662-4
56.Frieden, T. R. (2017). Evidence for health decision making: Beyond randomized trials. New England Journal of Medicine, 377(5), 465–475.
DOI: https://doi.org/10.1056/NEJMra1614394
57.Blonde, L., Khunti, K., Harris, S. B., Meizinger, C., & Skolnik, N. S. (2018). Interpretation and impact of real-world evidence. Diabetes, Obesity and Metabolism, 20(3), 541–546.
DOI: https://doi.org/10.1111/dom.13056
58.Corrigan-Curay, J., Sacks, L., & Woodcock, J. (2018). Real-world evidence and FDA. Clinical Pharmacology & Therapeutics, 103(6), 895–897.
DOI: https://doi.org/10.1002/cpt.1050
59.Sherman, R. E., Anderson, S. A., Dal Pan, G. J., et al. (2016). Real-world evidence—What is it and what can it tell us? New England Journal of Medicine, 375(23), 2293–2297.
DOI: https://doi.org/10.1056/NEJMsb1609216
60.Ford, I., & Norrie, J. (2016). Pragmatic trials. New England Journal of Medicine, 375(5), 454–463.
DOI: https://doi.org/10.1056/NEJMra1510059
61.Van Norman, G. A. (2021). Decentralized clinical trials: The future of medical product development? JACC: Basic to Translational Science, 6(4), 384–387.
DOI: https://doi.org/10.1016/j.jacbts.2021.03.009
62.Inan, O. T., Tenaerts, P., Prindiville, S. A., et al. (2020). Digitizing clinical trials. NPJ Digital Medicine, 3, 101.
DOI: https://doi.org/10.1038/s41746-020-0302-y
63.Goldsack, J. C., Coravos, A., Bakker, J. P., et al. (2020). Verification, analytical validation, and clinical validation of digital measures. NPJ Digital Medicine, 3, 93.
DOI: https://doi.org/10.1038/s41746-020-0265-z
64.Coravos, A., Goldsack, J. C., Karlin, D. R., et al. (2020). Digital medicine: A primer on measurement. NPJ Digital Medicine, 3, 47.
DOI: https://doi.org/10.1038/s41746-020-0254-2
65.Marra, C., Chen, J. L., Coravos, A., & Stern, A. D. (2020). Quantifying the use of connected digital products in clinical research. NPJ Digital Medicine, 3, 50.
DOI: https://doi.org/10.1038/s41746-020-0259-x
66.Khozin, S., Blumenthal, G. M., Pazdur, R. (2017). Real-world data for clinical evidence generation. Clinical Pharmacology & Therapeutics, 101(5), 624–626.
DOI: https://doi.org/10.1002/cpt.695

67. Makady, A., de Boer, A., Hillege, H., Klungel, O., & Goettsch, W. (2017). What is real-world data? Value in Health, 20(7), 858–865.
DOI: https://doi.org/10.1016/j.jval.2017.03.008
68.Berger, M. L., Sox, H., Willke, R. J., et al. (2017). Good practices for real-world data studies. Value in Health, 20(8), 1003–1008.
DOI: https://doi.org/10.1016/j.jval.2017.08.3019
69.Jarow, J. P., LaVange, L., & Woodcock, J. (2017). Multidimensional evidence generation. New England Journal of Medicine, 376(24), 2293–2297.
DOI: https://doi.org/10.1056/NEJMp1703671
70.Eichler, H. G., Sweeney, F. (2018). Real-world evidence in healthcare decision making. Clinical Pharmacology & Therapeutics, 103(2), 179–181.
DOI: https://doi.org/10.1002/cpt.939
71.Ashley, E. A. (2016). Towards precision medicine. Nature Reviews Genetics, 17(9), 507–522.
DOI: https://doi.org/10.1038/nrg.2016.86
72.Jameson, J. L., Longo, D. L. (2015). Precision medicine. New England Journal of Medicine, 372(23), 2229–2234.
DOI: https://doi.org/10.1056/NEJMsb1503104
73.Schork, N. J. (2015). Personalized medicine: Time for one-person trials. Nature, 520(7549), 609–611.
DOI: https://doi.org/10.1038/520609a
74.Collins, F. S., Morgan, M., & Patrinos, A. (2021). The Human Genome Project and precision medicine. Nature Medicine, 27, 1317–1327.
DOI: https://doi.org/10.1038/s41591-021-01462-z
75.Woodcock, J., LaVange, L. M. (2017). Master protocols to study multiple therapies. New England Journal of Medicine, 377(1), 62–70.
DOI: https://doi.org/10.1056/NEJMra1510062
76.Park, J. J. H., Siden, E., Zoratti, M. J., et al. (2019). Systematic review of basket, umbrella and platform trials. Lancet Oncology, 20(7), e345–e358.
DOI: https://doi.org/10.1016/S1470-2045(19)30300-4
77.Bothwell, L. E., Avorn, J., Khan, N. F., & Kesselheim, A. S. (2018). Adaptive trial designs. New England Journal of Medicine, 379(1), 65–74.
DOI: https://doi.org/10.1056/NEJMra1710061
78.Angus, D. C. (2022). Optimizing platform trials for future pandemics. JAMA, 327(23), 2271–2272.
DOI: https://doi.org/10.1001/jama.2022.7754
79.Topol, E. J. (2023). Artificial intelligence in medicine. The Lancet Digital Health, 5(2), e88–e95.
DOI: https://doi.org/10.1016/S2589-7500(22)00258-9
80.Ngiam, K. Y., & Khor, I. W. (2019). Artificial intelligence and machine learning in healthcare. Academic Medicine, 94(11), 1811–1816.
DOI: https://doi.org/10.1097/ACM.0000000000002830